The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
Abstract
BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VKAs are currently the only treatment with established safety in AF patients with rheumatic mitral valve disease and/or a mechanical heart valve prosthesis.400”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [400]
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081 · cited 4×
“Death, stroke, systemic embolism, or myocardial infarction 11 (8) 2 (3) 2 (6) 0 13 (8) 2 (2) 3.”
InfluentialThromboembolic and bleeding complications in patients with mechanical heart valve prostheses.
Cannegieter, S. C., Rosendaal, F. R., & Briët, E. (1994) · Circulation · doi:10.1161/01.cir.89.2.635 · Cited by 1,072
Reilly, P. A., Lehr, T., Haertter, S., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Ezekowitz, M. D., Nehmiz, G., Wang, S., & Wallentin, L. C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.104 · Cited by 838
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Self-citationLiesenfeld, K., Lehr, T., Dansirikul, C., Reilly, P., Connolly, S., Ezekowitz, M., Yusuf, S., Wallentin, L., Haertter, S., & Staab, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 333
Stassano, P., Tommaso, L. D., Monaco, M., Iorio, F., Pepino, P., Spampinato, N., & Vosa, C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.032 · Cited by 307
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 294
Sun, J. C. J., Davidson, M., Lamy, A. L., & Eikelboom, J. W. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60780-7 · Cited by 241
de Werf, F. V., Brueckmann, M., Connolly, S. J., Friedman, J. E., Granger, C. B., Härtter, S., Harper, R., Kappetein, A. P., Lehr, T., Mack, M. J., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.03.011 · Cited by 185
Lehr, T., Haertter, S., Liesenfeld, K., Staab, A., Clemens, A., Reilly, P. A., & Friedman, J. E. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011417716 · Cited by 96
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves
McKellar, S. H., Abel, S. A., Camp, C. L., Suri, R. M., Ereth, M. H., & Schaff, H. V. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.02.011 · Cited by 85
Mäegdefessel, L., Linde, T., Krapiec, F., Hamilton, K. F., Steinseifer, U., van Ryn, J., Raaz, U., Buerke, M., Werdan, K., & Schlitt, A. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.06.011 · Cited by 52
Lehr, T., Liesenfeld, K.-H., Haertter, S., Staab, A., & Dansirikul, C. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0656 · Cited by 48
Kaeberich, A., Reindl, I., Raaz, U., Mäegdefessel, L., Vogt, A., Linde, T., Steinseifer, U., Perzborn, E., Hauroeder, B., Buerke, M., et al. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0621-6 · Cited by 36
Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve.
Dewanjee, M. K., Gross, D. R., Zhai, P., Lanzo, S., Shim, H. S., Park, K., Schaeffer, D. J., & Twardock, A. R. (1999) · PubMed · Cited by 26
Dabigatran versus Warfarin after Mechanical Mitral Valve Replacement in the Swine Model
Schomburg, J. L., Medina, E., Lahti, M. T., & Bianco, R. W. (2012) · Journal of Investigative Surgery · doi:10.3109/08941939.2011.616256 · Cited by 24
Flagged first, then by citations
1 of the 27 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Dewanjee MK, 1999, J Heart Valve Dis, 8, 324
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
Metadata
- Authors
- Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
- Affiliations
- Hamilton Health Sciences (CA)
- Boehringer Ingelheim (Germany) (DE)
- Duke University (US)
- Erasmus MC (NL)
- Heart Hospital Baylor Plano (US)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (France) (FR)
- KU Leuven (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-26
- Volume
- 369
- Issue
- 13
- Pages
- 1206-1214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2016875529
- Cited by
- 1,506
- References
- 27
- Citations by year
- 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
- FWCI
- 97.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
- MeSH terms
- Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
